RecruitingNot ApplicableNCT06926153

Interventional Study on Smoking Reduction in Psychiatry

Evaluation of an Intervention to Reduce Smoking Among Mental Health Users Treated in Ambulatory Psychiatry


Sponsor

GCS-CCOMS

Enrollment

6,500 participants

Start Date

Jan 15, 2025

Study Type

INTERVENTIONAL

Summary

The smoking rate among people with mental disorders is higher than in the general population. Greater exposure to the harmful effects of tobacco partly explains the major inequality in life expectancy observed among people with mental disorders who, depending on the disorder and the study, live 10 to 25 years less than the general population, a gap mainly due to the occurrence of cardiovascular and respiratory pathologies, notably bronchial cancers. However, tobacco reduction actions specifically targeting these people remain insufficiently developed, particularly in psychiatry where this addiction is often banalized and its treatment neglected. The objective of this study is to evaluate an intervention ('Tabapsy') co-constructed with mental health services users, mental health professionals, and general practitioners and targeting adult patients followed in ambulatory psychiatry. The main objective is to evaluate the effectiveness of the intervention on short-term smoking cessation (cessation for at least 7 days) among regular smokers at 3 months. Secondary objectives include evaluation of its cost-effectiveness and implementation. To this end, a national cluster-randomized controlled study will be carried out, supplemented by qualitative interviews to study the implementation of the intervention.


Eligibility

Min Age: 18 Years

Inclusion Criteria5

  • Regular smokers (at least one cigarette per day)
  • Followed in psychiatric ambulatory care at one of the participating sectors' CMPs
  • Adults (18 years or older)
  • Covered by the statuary health insurance
  • Who gave their informed consent to participate to the study

Exclusion Criteria3

  • Users under guardianship or legal protection,
  • Psychological state incompatible with completing the questionnaire,
  • Persons with no command or understanding of the French language

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

OTHERTABAPSY

The Tabapsy intervention consists in a campaign to promote smoking cessation within the CMP, and an intervention to help people stop smoking which comprises of a) A general information meeting; b) An assessment workshop, to evaluate level of dependence using validated tests and establish a personalized cessation program based on the results obtained; c) Five thematic workshops to support cessation, covering 1/ nicotine replacement treatments, electronic cigarettes and other drug treatments available for smoking cessation, 2/ emotional management, 3/ weight gain, 4/ physical activities, and 5/ manual occupations; d) Peer support groups, based on the sharing of experiences, to encourage mutual aid and solidarity between people with mental disorders who are trying to quit smoking. The intervention relies on a facilitator specifically recruited to implement and run the intervention in the CMP. It is complemented by a website that will contain all the resources and information presented dur

OTHERUsual Care

Usual care corresponds to usual practices regarding smoking cessation activities in participating sectors. Those practices may vary (enquiring whether a patient is a smoker or not, offering smoking cessation if they are or only if the patient asks, etc.)


Locations(22)

Public mental health establishment of Lille Metropole (59G16-G17)

Armentières, France

Public mental health establishment of Lille Metropole (59G21)

Armentières, France

Flanders public mental health establishment (59G05/06)

Bailleul, France

Barthelemy Durand public health establishment (91G05)

Étampes, France

Psychotherapeutic center of Nancy (54G02-06)

Laxou, France

University Hospital Center of Lille (59G08)

Lille, France

Hospital Care Center of Nanterre (92G10)

Nanterre, France

University Hospital Group Paris Neurosciences & Psychiatry (75G04)

Paris, France

Hospital Center of Rouffach (68G02/03)

Rouffach, France

Hospital Center of Rouffach (68G08/09)

Rouffach, France

Hospital Center of Rouffach (Pôle LTD - 68G04/05)

Rouffach, France

Hospitals of Paris Est Val de Marne (94G01)

Saint-Maurice, France

Hospitals of Paris Est Val de Marne (94G16)

Saint-Maurice, France

Hospitals of Paris Est Val de Marne (Paris 11)

Saint-Maurice, France

Hospitals of Paris Est Val de Marne (Paris 12)

Saint-Maurice, France

Hospitals of Paris Est Val de Marne (Paris Centre)

Saint-Maurice, France

Public mental health establishment of Val de Lys Artois (62G09)

Saint-Venant, France

Public mental health establishment of Val de Lys Artois (62G12)

Saint-Venant, France

Public mental health establishment of Val de Lys Artois (Pôle du Ternois)

Saint-Venant, France

Public mental health establishment of Guadeloupe (96G01)

Saint-Claude, Guadeloupe

Public mental health establishment of Guadeloupe (96G06)

Saint-Claude, Guadeloupe

Public mental health establishment of Reunion Island (Pôle Nord)

Saint-Paul, Reunion

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06926153